WT161 is a potent,selective,and bioavailable HDAC6 inhibitor. It was created to study the mechanism of action of HDAC6 inhibition in MM (Multiple Myeloma) alone and in combination with Bortezomib (BTZ). WT161 in combination with BTZ triggers significant accumulation of polyubiquitinated proteins and cell stress, followed by caspase activation and apoptosis. More importantly, this combination treatment was effective in BTZ-resistant cells and in the presence of bone marrow stromal cells, which have been shown to mediate MM cell drug resistance. The activity of WT161 was confirmed in our human MM cell xenograft mouse model and established the framework for clinical trials of the combination treatment to improve patient outcomes in MM.

KEYWORDS: WT-161 | Supplier | HDAC6 inhibitor | WT161 | WT 161 | CT-WT161 | CAS [1206731-57-8] | Histone | HDAC | Inhibitor | Enzymes